Concepts (204)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Blood Coagulation | 5 | 2024 | 29 | 1.660 |
Why?
|
| Anticoagulants | 5 | 2024 | 122 | 1.260 |
Why?
|
| Factor XIIa | 3 | 2024 | 3 | 1.160 |
Why?
|
| Factor XIa | 3 | 2022 | 4 | 1.070 |
Why?
|
| Thrombosis | 2 | 2022 | 81 | 0.740 |
Why?
|
| Pentamidine | 2 | 2019 | 11 | 0.730 |
Why?
|
| Fibrinolysis | 1 | 2019 | 2 | 0.610 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2019 | 46 | 0.580 |
Why?
|
| Lipid Bilayers | 3 | 2007 | 57 | 0.540 |
Why?
|
| Thermodynamics | 4 | 2010 | 229 | 0.510 |
Why?
|
| Membrane Proteins | 3 | 2014 | 561 | 0.460 |
Why?
|
| Models, Molecular | 10 | 2024 | 876 | 0.450 |
Why?
|
| Antineoplastic Agents | 5 | 2024 | 1019 | 0.440 |
Why?
|
| Histone Deacetylases | 1 | 2015 | 61 | 0.430 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2024 | 159 | 0.360 |
Why?
|
| Prothrombin Time | 2 | 2023 | 8 | 0.350 |
Why?
|
| Biomimetic Materials | 1 | 2007 | 24 | 0.270 |
Why?
|
| Catalytic Domain | 3 | 2024 | 118 | 0.260 |
Why?
|
| Mutation | 3 | 2024 | 1177 | 0.260 |
Why?
|
| Alamethicin | 1 | 2006 | 8 | 0.240 |
Why?
|
| Cathepsin G | 1 | 2026 | 3 | 0.240 |
Why?
|
| Membrane Lipids | 1 | 2006 | 30 | 0.240 |
Why?
|
| Heparin | 1 | 2026 | 40 | 0.240 |
Why?
|
| Allosteric Site | 2 | 2022 | 12 | 0.230 |
Why?
|
| Amides | 1 | 2005 | 71 | 0.210 |
Why?
|
| Humans | 18 | 2026 | 43102 | 0.210 |
Why?
|
| Structure-Activity Relationship | 6 | 2026 | 506 | 0.210 |
Why?
|
| Neoplasms | 1 | 2015 | 1377 | 0.210 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2024 | 139 | 0.200 |
Why?
|
| Animals | 14 | 2024 | 16992 | 0.200 |
Why?
|
| Thrombin Time | 2 | 2020 | 2 | 0.200 |
Why?
|
| Partial Thromboplastin Time | 2 | 2020 | 9 | 0.200 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2024 | 257 | 0.190 |
Why?
|
| Factor XIIIa | 1 | 2022 | 1 | 0.190 |
Why?
|
| Ethacrynic Acid | 1 | 2022 | 2 | 0.190 |
Why?
|
| Antifibrinolytic Agents | 1 | 2022 | 4 | 0.190 |
Why?
|
| Models, Biological | 1 | 2006 | 712 | 0.190 |
Why?
|
| Factor IX | 1 | 2022 | 3 | 0.180 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2024 | 307 | 0.180 |
Why?
|
| Cell Proliferation | 6 | 2024 | 1455 | 0.170 |
Why?
|
| Computer Simulation | 4 | 2010 | 408 | 0.170 |
Why?
|
| Skin Neoplasms | 3 | 2011 | 178 | 0.170 |
Why?
|
| Drug Design | 2 | 2019 | 186 | 0.160 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2020 | 31 | 0.160 |
Why?
|
| Hydroxamic Acids | 1 | 2019 | 33 | 0.150 |
Why?
|
| Factor VIIa | 1 | 2019 | 2 | 0.150 |
Why?
|
| Blood Coagulation Tests | 1 | 2019 | 5 | 0.150 |
Why?
|
| Factor Xa | 1 | 2019 | 4 | 0.150 |
Why?
|
| Thrombin | 1 | 2019 | 28 | 0.150 |
Why?
|
| Estrogen Receptor alpha | 1 | 2020 | 121 | 0.150 |
Why?
|
| Sulfonamides | 1 | 2019 | 91 | 0.150 |
Why?
|
| Binding Sites | 5 | 2026 | 671 | 0.150 |
Why?
|
| Spastic Paraplegia, Hereditary | 1 | 2017 | 6 | 0.130 |
Why?
|
| Skin Aging | 1 | 2016 | 10 | 0.120 |
Why?
|
| Sunscreening Agents | 1 | 2016 | 11 | 0.120 |
Why?
|
| Mice | 9 | 2024 | 6644 | 0.120 |
Why?
|
| Flavanones | 1 | 2016 | 15 | 0.120 |
Why?
|
| Hydrogen Bonding | 2 | 2007 | 144 | 0.120 |
Why?
|
| Carbonic Anhydrase Inhibitors | 1 | 2015 | 7 | 0.120 |
Why?
|
| Carbonic Anhydrase II | 1 | 2015 | 3 | 0.120 |
Why?
|
| Cell Line, Tumor | 6 | 2024 | 2676 | 0.120 |
Why?
|
| Keratinocytes | 1 | 2016 | 67 | 0.120 |
Why?
|
| Ultraviolet Rays | 1 | 2016 | 118 | 0.120 |
Why?
|
| Dizocilpine Maleate | 1 | 2015 | 43 | 0.120 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 105 | 0.110 |
Why?
|
| Bile Acids and Salts | 1 | 2015 | 37 | 0.110 |
Why?
|
| Protein Structure, Secondary | 2 | 2006 | 182 | 0.110 |
Why?
|
| Piperidines | 1 | 2015 | 83 | 0.110 |
Why?
|
| Antigen-Presenting Cells | 1 | 2014 | 31 | 0.110 |
Why?
|
| Protein Conformation | 2 | 2006 | 416 | 0.110 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2015 | 135 | 0.110 |
Why?
|
| Immunity, Cellular | 1 | 2014 | 74 | 0.110 |
Why?
|
| Bibenzyls | 1 | 2014 | 4 | 0.110 |
Why?
|
| Tubulin Modulators | 1 | 2014 | 20 | 0.110 |
Why?
|
| Glycyrrhiza | 1 | 2013 | 1 | 0.100 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2013 | 4 | 0.100 |
Why?
|
| Thiazoles | 1 | 2014 | 76 | 0.100 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2013 | 32 | 0.100 |
Why?
|
| Drug Discovery | 2 | 2024 | 108 | 0.100 |
Why?
|
| Signal Transduction | 2 | 2014 | 2157 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 734 | 0.100 |
Why?
|
| Pyridines | 1 | 2014 | 139 | 0.100 |
Why?
|
| Isoflavones | 1 | 2013 | 132 | 0.090 |
Why?
|
| Melanoma | 1 | 2013 | 110 | 0.090 |
Why?
|
| DNA | 1 | 2015 | 592 | 0.090 |
Why?
|
| Xanthenes | 1 | 2011 | 11 | 0.090 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 386 | 0.090 |
Why?
|
| Epidermis | 1 | 2011 | 23 | 0.090 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 22 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2024 | 260 | 0.090 |
Why?
|
| Sunlight | 1 | 2011 | 48 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2011 | 108 | 0.090 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 98 | 0.090 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2011 | 14 | 0.090 |
Why?
|
| Flavonols | 1 | 2011 | 19 | 0.090 |
Why?
|
| Flavonoids | 1 | 2011 | 100 | 0.080 |
Why?
|
| Phosphatidylinositols | 1 | 2010 | 13 | 0.080 |
Why?
|
| Inositol | 1 | 2010 | 20 | 0.080 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2010 | 59 | 0.080 |
Why?
|
| Mice, Nude | 3 | 2020 | 408 | 0.080 |
Why?
|
| MAP Kinase Signaling System | 1 | 2011 | 196 | 0.080 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2020 | 347 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 3 | 2017 | 423 | 0.080 |
Why?
|
| MicroRNAs | 1 | 2015 | 518 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 1723 | 0.070 |
Why?
|
| Solubility | 1 | 2007 | 139 | 0.070 |
Why?
|
| Protein Subunits | 1 | 2007 | 93 | 0.070 |
Why?
|
| Molecular Conformation | 1 | 2007 | 155 | 0.060 |
Why?
|
| Solvents | 1 | 2007 | 113 | 0.060 |
Why?
|
| Brain | 1 | 2015 | 1472 | 0.060 |
Why?
|
| Protons | 1 | 2007 | 94 | 0.060 |
Why?
|
| Phosphorylation | 3 | 2016 | 986 | 0.060 |
Why?
|
| Dimerization | 1 | 2006 | 112 | 0.060 |
Why?
|
| Blotting, Western | 3 | 2013 | 883 | 0.060 |
Why?
|
| Membrane Potentials | 1 | 2006 | 222 | 0.060 |
Why?
|
| Protein Binding | 2 | 2020 | 1082 | 0.060 |
Why?
|
| Amino Acids | 1 | 2006 | 148 | 0.060 |
Why?
|
| Alanine | 1 | 2005 | 34 | 0.060 |
Why?
|
| Threonine | 1 | 2005 | 24 | 0.060 |
Why?
|
| Bacteriorhodopsins | 1 | 2005 | 33 | 0.060 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 97 | 0.060 |
Why?
|
| Lactams | 1 | 2024 | 10 | 0.060 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2006 | 301 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2024 | 26 | 0.050 |
Why?
|
| Chick Embryo | 2 | 2014 | 79 | 0.050 |
Why?
|
| Blood Proteins | 1 | 2024 | 77 | 0.050 |
Why?
|
| Transcription Factor AP-1 | 2 | 2016 | 34 | 0.050 |
Why?
|
| Pyrazoles | 1 | 2024 | 103 | 0.050 |
Why?
|
| Models, Chemical | 1 | 2005 | 204 | 0.050 |
Why?
|
| Carbon | 1 | 2005 | 128 | 0.050 |
Why?
|
| Oxygen | 1 | 2005 | 218 | 0.050 |
Why?
|
| Amino Acid Sequence | 1 | 2006 | 1180 | 0.050 |
Why?
|
| Flow Cytometry | 2 | 2014 | 411 | 0.050 |
Why?
|
| Rats | 2 | 2024 | 3735 | 0.050 |
Why?
|
| Fibrin | 1 | 2022 | 10 | 0.050 |
Why?
|
| Patents as Topic | 1 | 2022 | 14 | 0.050 |
Why?
|
| Hemorrhage | 1 | 2022 | 55 | 0.040 |
Why?
|
| Cell Cycle | 2 | 2013 | 346 | 0.040 |
Why?
|
| Quercetin | 2 | 2011 | 46 | 0.040 |
Why?
|
| Enzyme Assays | 1 | 2020 | 13 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2011 | 165 | 0.040 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2019 | 140 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 2 | 2014 | 1869 | 0.040 |
Why?
|
| Female | 5 | 2020 | 24698 | 0.030 |
Why?
|
| Biocatalysis | 1 | 2017 | 30 | 0.030 |
Why?
|
| Binding, Competitive | 1 | 2017 | 109 | 0.030 |
Why?
|
| Hydrolysis | 1 | 2017 | 97 | 0.030 |
Why?
|
| Magnesium | 1 | 2017 | 94 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2017 | 206 | 0.030 |
Why?
|
| Protein Multimerization | 1 | 2017 | 115 | 0.030 |
Why?
|
| Microtubules | 1 | 2017 | 121 | 0.030 |
Why?
|
| Mice, Hairless | 1 | 2016 | 7 | 0.030 |
Why?
|
| Manganese | 1 | 2017 | 92 | 0.030 |
Why?
|
| Butadienes | 1 | 2016 | 29 | 0.030 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2016 | 26 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2016 | 23 | 0.030 |
Why?
|
| Luciferases | 1 | 2016 | 71 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2017 | 518 | 0.030 |
Why?
|
| Genes, Reporter | 1 | 2016 | 148 | 0.030 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2017 | 188 | 0.030 |
Why?
|
| Nitriles | 1 | 2016 | 81 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2016 | 83 | 0.030 |
Why?
|
| Tritium | 1 | 2015 | 46 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2016 | 152 | 0.030 |
Why?
|
| Chorioallantoic Membrane | 1 | 2014 | 11 | 0.030 |
Why?
|
| Piperazines | 1 | 2015 | 120 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 95 | 0.030 |
Why?
|
| Colchicine | 1 | 2014 | 15 | 0.030 |
Why?
|
| Laminin | 1 | 2014 | 58 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2014 | 49 | 0.030 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 72 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2014 | 104 | 0.030 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 62 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 157 | 0.030 |
Why?
|
| Glycyrrhizic Acid | 1 | 2013 | 4 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2014 | 80 | 0.030 |
Why?
|
| Water | 1 | 2016 | 316 | 0.030 |
Why?
|
| Tubulin | 1 | 2014 | 96 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2013 | 127 | 0.030 |
Why?
|
| Collagen | 1 | 2014 | 181 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 455 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 290 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2014 | 237 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2013 | 238 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2013 | 508 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2014 | 321 | 0.020 |
Why?
|
| Cell Line | 1 | 2016 | 1410 | 0.020 |
Why?
|
| Medicine, Chinese Traditional | 1 | 2011 | 8 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2013 | 694 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2011 | 41 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2013 | 187 | 0.020 |
Why?
|
| Transcriptional Activation | 1 | 2011 | 173 | 0.020 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 1070 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2011 | 107 | 0.020 |
Why?
|
| Cell Movement | 1 | 2014 | 655 | 0.020 |
Why?
|
| Static Electricity | 1 | 2010 | 86 | 0.020 |
Why?
|
| Stereoisomerism | 1 | 2010 | 169 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2010 | 219 | 0.020 |
Why?
|
| Ligands | 1 | 2010 | 388 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 934 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2011 | 1621 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2010 | 1081 | 0.020 |
Why?
|
| Apoptosis | 1 | 2013 | 1568 | 0.010 |
Why?
|
| Male | 1 | 2013 | 23409 | 0.010 |
Why?
|